Boston-based Dana-Farber Cancer Institute recorded an operating income of $91.5 million (8.4% operating margin) in the first quarter of 2026, up from $69.1 million (7% margin) during the same period last year, according to its March 11 financial report.
Dana-Farber recorded total operating revenue of $1.1 billion for the three months ended Dec. 31, up from $982.8 million during the same period last year. Net patient service revenue was $822.3 million, up from $727.9 million. Dana-Farber attributed the 13% year-over-year growth in net patient service revenue to an increase in patient volume and pharmacy revenue. Clinic visits grew 3.9% year over year and infusion visits increased 6.7%. Direct research revenue was $148.7 million, up from $137.1 million.
Total operating expenses were $1 billion in the first quarter of 2026, up from $910.5 million during the same period last year. Total patient service expenses were $670.2 million, up from $590 million. Total research expenses were $171.8 million, up from $158.6 million. Total general and administrative expenses were $158.6 million, down from $161.8 million, which the system attributed to a decrease in legal and consulting expenses.
Dana-Farber recorded a net income of $133 million in the first quarter of 2026, up from $108.4 million during the same period last year.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
